Upadacitinib for eye inflammation in patients with spinal arthritis
Treatments studied
Part of Bones, joints & muscles, Eyes & vision clinical trials.
This study tests whether the medicine upadacitinib (a pill that reduces inflammation) can reduce the number of acute uveitis flare-ups (eye inflammation) in people with axial spondyloarthritis (a type of arthritis affecting the spine). It may help prevent these painful eye episodes if you have them alongside your arthritis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with axial spondyloarthritis (a type of arthritis affecting the spine).
- You have had at least one episode of acute anterior uveitis (eye inflammation) in the past year.
- Your arthritis is active, meaning you have significant pain and stiffness despite treatment.
- You have tried at least two different NSAIDs (pain relievers like ibuprofen) without success or couldn't tolerate them.
- You are either new to biologic medicines or have tried them without success.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
This study tests how well upadacitinib (a pill taken daily) works for people with active psoriatic arthritis that also affects the spine. It is for those who have not responded well enough to other treatments like NSAIDs or biologics.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
This study compares two newer medicines (an IL-17 inhibitor and a JAK inhibitor) for people with axial spondyloarthritis whose previous TNF inhibitor did not work or caused side effects. The goal is to see which one works better for controlling symptoms.
This study tests whether a higher dose of upadacitinib (45 mg) can help people with ulcerative colitis whose symptoms come back while on the usual 30 mg maintenance dose. If you've lost response to your current treatment, this re-induction approach may help you get back into remission.
This study tests if the medication upadacitinib can help people whose eyelid rash has not improved with prescription creams. It's for adults who have had eyelid dermatitis for at least two months and have tried at least one prescribed cream that didn't work.
Hear when a new Axial Spondylarthritis (axSpA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.